Table 1.
Baseline characteristics of 351 patients treated with neoadjuvant therapy followed by esophagectomy or primary surgery for esophageal cancer
| Neoadjuvant therapy total (n = 214) n (%)* | Primary surgery total (n = 137) n (%)* | |
|---|---|---|
| Age at diagnosis, year [mean ± SD] | 63 (8.4) | 64 (9.9) |
| Gender | ||
| Male | 171 (80) | 93 (68) |
| Female | 43 (20) | 44 (32) |
| ASA score | ||
| 1 | 49 (23) | 35 (26) |
| 2 | 136 (64) | 70 (51) |
| ≥3 | 29 (14) | 32 (23) |
| Tumor location | ||
| Upper esophagus | 3 (1) | 0 (0) |
| Middle esophagus | 30 (14) | 29 (21) |
| Distal esophagus | 105 (49) | 62 (45) |
| Gastroesophageal junction | 76 (36) | 46 (34) |
| Neoadjuvant therapy | ||
| None | 0 (0) | 137 (100) |
| Chemotherapy | 103 (48) | 0 (0) |
| Chemoradiotherapy | 111 (52) | 0 (0) |
| Surgical approach | ||
| Transthoracic | 176 (82) | 84 (61) |
| Transhiatal | 38 (18) | 53 (39) |
| Histological type | ||
| Adenocarcinoma | 175 (82) | 92 (67) |
| Squamous cell carcinoma | 39 (18) | 44 (32) |
| Other | 0 (0) | 1 (1) |
| pT stage | ||
| T0 | 39 (18) | 2 (2) |
| T1-2 | 64 (30) | 39 (28) |
| T3-4a | 111 (51) | 96 (70) |
| pN stage | ||
| N0 | 108 (51) | 46 (34) |
| N1 | 54 (25) | 39 (29) |
| N2-3 | 52 (24) | 52 (38) |
| Radicality | ||
| R0 | 198 (93) | 117 (85) |
| R1 | 16 (8) | 20 (15) |
| Referral | ||
| By general practitioner | 23 (11) | 34 (25) |
| By another hospital | 191 (89) | 103 (75) |
| Year of diagnosis | ||
| 2003–2005 | 2 (1) | 34 (25) |
| 2006–2008 | 22 (10) | 50 (36) |
| 2009–2011 | 91 (43) | 33 (24) |
| 2012–2014 | 99 (46) | 20 (15) |
SD standard deviation, ASA American Society of Anesthesiologists
* Percentages may not add up to 100 due to rounding